English 
Francais 
عربي 
Cancer: hope in the form of an immunosuppressant
[mis à jour le 10 October 2006 à 07h48]
The process of angiogenesis, which is behind the development of a cancerous tumour, is currently the subject of dozens of studies all over the world. One of them mentions the "real potential" of a molecule which until now has been used to prevent the rejection of transplants.
According to researchers at Beth Israel Deaconess Medical Center in Boston, rapamycin is capable of inhibiting angiogenesis. Based on work on mice, they observed that this molecule reduced tumour growth as well as the flow of blood in blood vessels. Such promising results that rapamycin is currently being tested in clinical trials in the United States.
Source: Cancer Cell, August 2006
Print this article
Share on Facebook
Share on Twitter
Send to a friend
Convert to pdf
Copyright Authorization
11 article(s)
Obesity and cancer – the risk varies with gender
Obesity and cancer – the risks vary with gender
New blood screening hope for lung cancer
Paediatric Cancer – keeping a look-out for long-term secondary effects
Vaccinating against cervical cancer - and not just young girls!
Cancer immunotherapy - the story of an unrelenting quest
Curing Breast Cancer: new horizons open up
Does tongue cancer come from the gums?
